Scientific deep-dive

Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Showed and the FDA's First-Ever OSA Drug Approval

In SURMOUNT-OSA, tirzepatide cut the apnea-hypopnea index by 25 to 29 events per hour, with and without CPAP, in adults with moderate-to-severe sleep apnea and obesity. The trial led to Zepbound becoming the first FDA-approved drug for obstructive sleep apnea.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·4 citations

Until 2024, the standard pharmacological treatment for obstructive sleep apnea (OSA) was nothing — there wasn't one. CPAP machines and oral appliances were the only options, and roughly two-thirds of patients prescribed CPAP don't tolerate it long-term. The SURMOUNT-OSA trial, published in the New England Journal of Medicine on October 3, 2024 [1], changed that. Tirzepatide cut the apnea-hypopnea index by 25–29 events per hour from a baseline of around 50, both in patients actively using CPAP and patients who weren't. The FDA followed with what its own press release describes as the first medication ever approved for obstructive sleep apnea [2]. Here's what the trial actually showed and what it changes for the millions of obese adults living with sleep apnea.

Why this trial mattered before it ran

Obstructive sleep apnea is the most common sleep-disordered breathing condition in adults. It's strongly associated with obesity — visceral fat around the upper airway and neck contributes to the airway collapse that defines the disease. For decades, clinicians have observed that significant weight loss (typically via bariatric surgery) reduces OSA severity, sometimes dramatically. But until SURMOUNT-OSA, no randomized trial had specifically tested whether a pharmacological weight-loss intervention could deliver the same benefit on a measurable apnea endpoint.

The clinical context made the question urgent. Standard OSA treatment is positive airway pressure (PAP) therapy — delivered via CPAP, BiPAP, or APAP machines that hold the airway open with pressurized air during sleep. PAP works when patients use it, but long-term adherence is a well-documented clinical problem in sleep medicine: a substantial fraction of patients prescribed CPAP either abandon the therapy or use it inconsistently within the first year, though published adherence rates vary widely by study population, definition of “adherent,” and follow-up duration. For non-adherent patients, the remaining options before SURMOUNT-OSA were oral appliances (modest efficacy), positional therapy (very limited), and bariatric surgery (effective but invasive and inappropriate for most patients).

A pharmacological option that worked even in patients who couldn't tolerate CPAP would change the standard of care. SURMOUNT-OSA was designed to find out whether tirzepatide could be that option.

SURMOUNT-OSA trial design

SURMOUNT-OSA was actually two parallel randomized trials, run simultaneously and reported together [1]:

  • Trial 1 — PAP-naïve cohort: patients with moderate-to-severe OSA and obesity who were NOT using PAP therapy at baseline. Mean baseline AHI was 51.5 events per hour. Mean baseline BMI was 39.1 kg/m².
  • Trial 2 — PAP-treated cohort: patients with moderate-to-severe OSA and obesity who WERE using PAP therapy at baseline and continued PAP throughout the trial. Mean baseline AHI (on PAP) was 49.5 events per hour. Mean baseline BMI was 38.7 kg/m².

Both trials were phase 3, double-blind, placebo-controlled, randomized, and ran for 52 weeks. Participants in the tirzepatide arms received the maximum tolerated dose (10 mg or 15 mg subcutaneously weekly) per the standard SURMOUNT titration schedule. The primary endpoint in both trials was absolute change in AHI (apnea-hypopnea events per hour of sleep) from baseline to week 52, measured by polysomnography in a sleep lab — the gold-standard objective measurement of OSA severity [1].

The primary results

Both trials hit their primary endpoint with comfortable statistical margins [1]:

TrialTirzepatide AHI changePlacebo AHI changeTreatment difference
Trial 1 — PAP-naïve−25.3 events/hour−5.3 events/hour−20.0 events/hour (P<0.001)
Trial 2 — PAP-treated−29.3 events/hour−5.5 events/hour−23.8 events/hour (P<0.001)

From a baseline of approximately 50 events per hour (which meets the clinical definition of severe OSA), tirzepatide cut AHI by roughly half — to around 25 events per hour in the PAP-naïve group and around 20 events per hour in the PAP-treated group. For context, an AHI below 5 is considered normal, 5–15 is mild OSA, 15–30 is moderate, and 30+ is severe. SURMOUNT-OSA participants moved from severe OSA territory to the lower end of moderate OSA on average, and a meaningful subset moved into the mild range or below clinically meaningful thresholds entirely.

Magnitude comparison

Absolute change in apnea-hypopnea index (AHI, events per hour) from baseline to week 52 in SURMOUNT-OSA — tirzepatide vs placebo in Trial 1 (PAP-naïve) and Trial 2 (on PAP). Baseline AHI ~50 events/hour in both trials.[1]

  • Trial 1 (no CPAP) — placebo5.3 events/hour AHI reduction
  • Trial 1 (no CPAP) — tirzepatide25.3 events/hour AHI reduction
  • Trial 2 (on CPAP) — placebo5.5 events/hour AHI reduction
  • Trial 2 (on CPAP) — tirzepatide29.3 events/hour AHI reduction
    additive on top of CPAP
Absolute change in apnea-hypopnea index (AHI, events per hour) from baseline to week 52 in SURMOUNT-OSA — tirzepatide vs placebo in Trial 1 (PAP-naïve) and Trial 2 (on PAP). Baseline AHI ~50 events/hour in both trials.

What this means clinically

The 20-event-per-hour reduction in the PAP-naïve cohort is the more clinically remarkable result. These patients started the trial with no other OSA treatment, and tirzepatide alone — no CPAP, no oral appliance, no positional therapy — moved them from severe OSA to moderate. For patients who refuse or cannot tolerate PAP therapy, this is the first pharmacological intervention that delivers a clinically meaningful effect on the underlying disease, not just a downstream symptom.

The PAP-treated cohort result is also clinically interesting. Patients on tirzepatide PLUS PAP achieved an even larger AHI reduction (29.3 events/hour) than tirzepatide alone — but the most editorially important interpretation is that tirzepatide is additive to PAP rather than competing with it. Patients who currently tolerate CPAP and want to keep using it can add tirzepatide for a deeper response, while patients who don't tolerate CPAP have an alternative that works on its own.

Secondary endpoints

The published abstract [1] reports that all prespecified key secondary endpoints favored tirzepatide. These included measures the trial team selected because they capture the downstream consequences of OSA — the things that actually matter to patients beyond a number on a sleep study report:

  • Body weight reduction
  • Systolic blood pressure reduction
  • Hypoxic burden — a measure of how much time the patient spent with low blood oxygen during sleep, which is the mechanistic driver of most of OSA's long-term cardiovascular harm
  • High-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation associated with OSA
  • Patient-reported sleep disturbance measures

The published trial reports that all of these moved favorably with tirzepatide vs placebo. The exact magnitudes for individual secondary endpoints are detailed in the full NEJM publication; we're reporting at the level of statistical direction here because the abstract verifies the direction but not every magnitude [1].

The FDA approval

Following SURMOUNT-OSA's positive primary endpoint result, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The FDA's own press release describes this as the first medication ever approved by the agency for obstructive sleep apnea [2].

The approval matters as much for what it signals as for what it does directly. For decades, OSA has been treated as a mechanical problem — your airway closes, so we deliver pressurized air to hold it open. Tirzepatide approval marks the first time the FDA has accepted a pharmacological, weight-loss-mediated approach as a legitimate treatment for OSA itself. That precedent is likely to influence the regulatory and clinical conversation around adjacent pharmacological approaches over the coming years — see also the parallel evidence in our STEP-HFpEF semaglutide heart failure deep-dive for the same pattern playing out in heart failure.

For the most current label language, dosing information, and contraindications, refer to the official Zepbound prescribing information at the FDA's drug information portal [4].

Insurance coverage implications

The OSA approval is editorially significant for one reason most patients won't see in the press coverage: it creates a new covered indication for tirzepatide that some insurers will reimburse where they currently deny weight loss as the primary indication. Many commercial plans explicitly exclude GLP-1 / GIP-GLP-1 medications for weight loss alone, but those same plans typically cover the same drugs for an FDA-approved disease indication. Sleep apnea is now such an indication.

Patients with documented moderate-to-severe OSA whose insurance currently denies tirzepatide for weight loss should discuss with their prescriber whether the OSA indication may now provide a coverage path. Documentation requirements vary by insurer, but typically include a sleep study report with AHI and a treating physician's letter of medical necessity. See our GLP-1 insurance coverage audit for the per-insurer breakdown of how the major commercial plans handle GLP-1 prior authorization. For the verbatim Cigna IP0206 §V.2 OSA-pathway criteria (AHI ≥15, BMI ≥30, ≥10% weight loss to continue), see our Cigna GLP-1 Prior Authorization Guide.

Adverse events: same pattern as SURMOUNT-1

SURMOUNT-OSA reported that the most frequently observed adverse events with tirzepatide were gastrointestinal in nature, primarily mild to moderate in severity, and consistent with what was seen in the obesity-only trial SURMOUNT-1 [1, 3]. Translation: nausea during dose escalation, diarrhea, occasional vomiting and constipation, most resolving with continued use.

For the full GLP-1 / GIP-GLP-1 adverse event picture including the percentage breakdowns from SURMOUNT-1 and STEP-1, see our GLP-1 side effects investigation. The OSA population didn't expose any new safety signal — the patient cohort is essentially a subset of the obese adult population already studied at length in the SURMOUNT program.

What this changes for OSA patients

Most OSA patients are not going to switch to tirzepatide monotherapy and discard their CPAP machine. CPAP, when tolerated, is still highly effective and considerably cheaper. The clinical utility of tirzepatide for OSA is sharper for two specific patient populations:

  1. Patients with moderate-to-severe OSA + obesity who cannot tolerate CPAP. This is the largest unaddressed-need population in sleep medicine. Tirzepatide gives them, for the first time, an evidence-based alternative that actually changes the underlying disease rather than just a symptom.
  2. Patients on PAP therapy who also have obesity and want a deeper treatment response. The PAP-treated arm of SURMOUNT-OSA (Trial 2) showed that adding tirzepatide on top of CPAP produces a larger AHI reduction than CPAP alone, even in patients with good PAP adherence at baseline.

For both populations, the conversation with a sleep specialist now needs to include the tirzepatide option as a legitimate first-line consideration. That wasn't true 18 months ago.

What we don't yet know

SURMOUNT-OSA gave us 52 weeks of randomized data. The open questions for the next several years of clinical research:

  • Long-term durability. Does the AHI reduction persist past one year of treatment? What happens if patients lose insurance coverage and stop the drug? Based on the SURMOUNT-4 weight maintenance data for tirzepatide, the working assumption is that discontinuation will likely produce regain of both weight and AHI, but this needs direct measurement in OSA- specific populations.
  • Semaglutide for OSA. No semaglutide- specific OSA trial has been published. It's plausible that semaglutide produces comparable benefits given its effective weight loss profile, but absent direct trial data, the FDA-approved indication is currently limited to tirzepatide. For the broader efficacy comparison between the two drugs, see our tirzepatide vs semaglutide head-to-head deep dive.
  • Mechanism — weight loss alone, or more? The relationship between weight loss and AHI improvement has been clinically observed for decades, but the published quantitative literature doesn't yet decompose how much of the SURMOUNT-OSA benefit is purely weight loss vs how much is potential additional effects (upper airway fat, inflammatory tone, autonomic function). This is an active research question.
  • Head-to-head with CPAP. SURMOUNT-OSA measured tirzepatide vs placebo, not tirzepatide vs CPAP. A direct comparison would tell clinicians how to choose between the two for patients who could realistically use either.

The bottom line

SURMOUNT-OSA is the first randomized trial to demonstrate that a pharmacological intervention can produce a clinically meaningful reduction in objective obstructive sleep apnea severity. Tirzepatide cut AHI by roughly half from a severe baseline, both with and without concurrent CPAP. The FDA has since approved Zepbound for OSA in adults with obesity, making it the first prescription medication ever approved for the condition [2]. For the millions of obese adults who don't tolerate CPAP, this is the first credible alternative that addresses the disease itself rather than just compensating for its symptoms.

Further reading

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Yes — the SURMOUNT-OSA trial (Malhotra 2024, NEJM, PMID 38858710) randomized adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to tirzepatide vs placebo. After 52 weeks, tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 25-30 events per hour vs placebo, with about 50% of treated patients achieving disease resolution criteria. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024 based on these results.
Yes. The FDA added the moderate-to-severe obstructive sleep apnea indication to the Zepbound label in December 2024, making it the first drug approved specifically for OSA in adults with obesity. Coverage and prior authorization criteria for this indication vary by insurance plan and are evolving as the indication is new.
Not without a sleep study and clinician guidance. The SURMOUNT-OSA trial showed substantial AHI reduction, and about half of treated patients met disease resolution criteria — but individual response varies. The right path is to start tirzepatide alongside CPAP, then have a follow-up sleep study to objectively measure your AHI before discontinuing CPAP. Stopping CPAP without verified resolution puts you at cardiovascular and neurocognitive risk.
Wegovy has not had a dedicated phase 3 OSA trial published, and is NOT FDA-approved for OSA as of 2026. Mechanistically the weight loss should improve OSA, and observational data support this, but the FDA-approved evidence base for OSA specifically is limited to tirzepatide. If OSA is a primary indication, tirzepatide currently has the strongest evidence.
In SURMOUNT-OSA, tirzepatide reduced AHI by approximately 25-30 events per hour from baseline at 52 weeks, vs ~5 events/hour for placebo. The magnitude is comparable to or larger than what bariatric surgery produces. The reduction is durable as long as the drug is continued and weight loss is maintained.
Medicare coverage for Zepbound for obstructive sleep apnea depends on your specific plan. Medicare Part D excludes drugs used for weight loss, but OSA is a separate FDA-approved indication, so Part D plans can cover Zepbound when it is prescribed for sleep apnea, subject to each plan's formulary and prior authorization. Separately, from July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge gives eligible Part D enrollees the Zepbound KwikPen for weight loss at a $50 copay (single-dose vials and pens are not included). Some Medicare Advantage (Part C) plans have begun covering Zepbound under the sleep apnea indication - distinct from the weight-loss indication - so the right first step is to contact your plan directly and ask whether Zepbound is covered when prescribed for obstructive sleep apnea (ICD-10 code G47.33) rather than for obesity alone. Ask your prescriber to submit the prior authorization under the OSA indication and to include your sleep study AHI documentation; if denied, a letter of medical necessity and peer-to-peer review are the standard appeal path.
The SURMOUNT-OSA trial measured outcomes at 52 weeks, so the primary evidence for AHI reduction covers the full first year of treatment (Malhotra 2024, PMID 38912654). In practice, AHI improvement is tied to weight loss, which begins within the first four to eight weeks but accumulates progressively through the dose-escalation period; the largest AHI reductions in SURMOUNT-OSA corresponded to the greatest weight-loss trajectories. Some patients notice subjective improvements in daytime sleepiness and sleep quality earlier - often once five to ten percent of body weight has been lost - but objective AHI must be confirmed with a follow-up sleep study before any decision to reduce or discontinue CPAP. Plan for at least three to six months before a meaningful objective response can be documented, and confirm the response formally with polysomnography rather than relying on symptoms alone.

References

  1. 1.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID: 38912654.
  2. 2.U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (press release). FDA News & Events. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
  3. 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) Prescribing Information. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf

Zepbound for Sleep Apnea (OSA): The Patient Action Plan

Zepbound (tirzepatide) became the first FDA-approved drug for obstructive sleep apnea in December 2024, after SURMOUNT-OSA showed about 25-29 fewer breathing events per hour over 52 weeks in adults with obesity.

13 min read

Obesity Hypoventilation Syndrome (Pickwickian Syndrome): Diagnosis, CPAP and Weight Loss

Obesity hypoventilation syndrome (Pickwickian syndrome): how it is diagnosed, how common it is, its overlap with sleep apnea, what the Pickwick trials show for CPAP and noninvasive ventilation, and the evidence on weight loss, bariatric surgery and GLP-1 drugs.

11 min read

Does Losing Weight Stop Snoring? What the Evidence Shows

Does losing weight stop snoring? In heavy snorers who lost at least 3 kg, snores per hour fell from 320 to 176. How neck and tongue fat drive snoring, how simple snoring differs from sleep apnea, and when snoring is worth testing.

9 min read

GLP-1 Drugs and the DOT Physical: What Commercial Drivers Need

Obesity is roughly twice as common among long-haul drivers as in the general working population, and it drives the two conditions that most often complicate certification. What a GLP-1 changes about the DOT physical, and what it does not.

8 min read

Ozempic and Sleep: Insomnia, Sleep Quality & Sleep Apnea (2026)

Insomnia isn't a prominently labeled side effect of Ozempic (semaglutide), though it can disrupt sleep indirectly. The weight loss it drives often improves obstructive sleep apnea, and tirzepatide (Zepbound) is FDA-approved for moderate-to-severe OSA.

8 min read

Who Qualifies for GLP-1 Weight-Loss Medication? The FDA Label Criteria

Who qualifies for Wegovy, Zepbound, Saxenda, or Foundayo under the FDA labels: adult BMI rules, teen percentile rules, the heart, MASH, and sleep apnea approvals, how to calculate BMI, and why insurance criteria differ.

10 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo (+ required membership)

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $129/mo (“starting at” price)

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo (sale price)

Get started →